Search
EuroSIDA Publications 2018


Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, J Grarup, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich , R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren, A Mocroft on behalf of EuroSIDA.
HIV Med. 2018;19(2):102-117. abstract

2 Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro, J. A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, for the TB:HIV study in EuroCoord.
J Infect. 2018;76(1):44-54. Abstract

3 The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A for EuroSIDA in EuroCOORD.
HIV Med. 2018;19(2):90-101. Abstract 

4 Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? A Mocroft, K Laut, P Reiss, J Gatell, V Ormaasen, M Cavassini, V Hadziosmanovic, K Mansinho, C Pradier, M Vasylyev, V Mitsura, L Vandekerckhove, L Ostergaard, A Clarke, O Degen, F Mulcahy, A Castagna, Z Sthoeger, L Flamholc, D Sedláček, I Mozer-Lisewska, JD Lundgren for the EuroSIDA study.
AIDS. 2018;32(2):205-215. Abstract

5 Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort. A Roen, K Laut, A Pelchen-Matthews, E Borodulina, L Caldeira, A Clarke, B Clotet, A d'Arminio Monforte, G Fätkenheuer, JM. Gatell Artigas, IKarpov, A Kuznetsova, G Kyselyova, I Mozer-Lisewska, F Mulcahy, L Ragone, A Scherrer, V Uzdaviniene, L Vandekerckhove, V Vannappagari, L Ostergaard, A Mocroft for the EuroSIDA study
HIV Med. 2018;19(4):252-260. Abstract

6 Long-term Effectiveness of Recommended Boosted PI-Based Antiretroviral Therapy in Europe. Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Parades R, Lundgren JD for the EuroSIDA study. 
HIV Med. 2018;19(5):324-338. Abstract

7 Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.  Hatleberg CI,  Ryom L,  El-Sadr W,  Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law, M, Lundgren JD, Sabin C, On behalf of the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.
J Int AIDS Soc. 2018;21(3). Abstract

8 Abacavir use and risk of recurrent myocardial infarction.Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.
AIDS. 2018;32(1):79-88. Abstract

Total Publications April 2018: 272


IN PRESS

1The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, M Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri.
Antivir Ther. 2017  [Epub ahead of print]  Abstract 

2 Persistent disparities in ART-coverage and virological suppression across Europe. Laut KG, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, Kovari H, Blaxhult A, Zangerle R, Trofimora T, Knysz B, Zilmer K, Kouzovatova E, Staub T, Raben D, Lundgren JD, Mocroft A, Kirk O for the EuroSIDA study.
Eurosurveillance 2017

3 Uptake of tenofovir-based antiretroviral therapy among HIV/HBV co-infected patients in the EuroSIDA study. Peters L, Mocroft A. Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J for the EuroSIDA study.
Antivir Ther. 2018 [Epub ahead of print] Abstract

4 Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma.
L Shepherd, L Ryom, M Law, C Ingrid Hatleberg, S de Wit, A d'Arminio Monforte, M Battegay, A Phillips, F Bonnet, P Reiss, C Pradier, A Grulich, C Sabin, J Lundgren, A Mocroft,
J Natl Cancer Inst. 2017 [Epub ahead of print] Abstract

5 Association between Cardiovascular Disease & Use of Contemporary Protease Inhibitors: The D:A:D Study. L Ryom, JD Lundgren, W El-Sadr, P Reiss, O Kirk, M Law, A Phillips, R Weber, E Fontas, A d’ Arminio Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft. On behalf of the D:A:D Study group
Lancet HIV 2018